Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MorphoSys AG AGM Information 2011

May 19, 2011

291_ip_2011-05-19_9324edd2-2d9d-417e-9e32-77e1dabc42ef.pdf

AGM Information

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Annual General Meeting 2011

Annual General Meeting 2011 Agenda

    1. P t ti f th fi d l fi i l t t t f D b 31 2010 th Presentation of the confirme d annual financial statements as of December 31, 2010, the management report together with the consolidated financial statements, the consolidated management report and the report of the Supervisory Board for the business year 2010 and the statement of the Board of Management to the items pursuant to § § 289 para 4 315 para 4 HGB para. 4, para. HGB
    1. Formal approval on behalf of the Board of Management
    1. Formal approval on behalf of the Supervisory Board
  • 4.Appointment of the auditors for the business year 2011 for year
    1. New Election to the Supervisory Board
    1. Resolution on the Approval of the Remuneration Scheme of Members of the Board of Management
    1. Resolution on the Authorization to purchase and use Treasur y Stock and on the Exclusion of Subscription Rights
    1. Creation of a new Conditional Capital 2011-I, authorization on behalf of the Board of Management t i ti d/ tibl b d l i f S b i ti Ri ht A d t f th to issue option and/or convertible bonds, exclusion of ubscription Rights; Amendment of the Articles
    1. Compensation of the Supervisory Board by Secondary Payments of the Company, Amendment of the Articles

Management Report

New Chief Financial Officer of MorphoSys AG Jens Holstein

  • New CFO since May 01, 2011
  • Last Position: Regional CFO Europe & Middle East of Fresenius Kabi AG, Managing Director of Fresenius Kabi Kabi Deutschland GmbH
  • Since 1995: Various financial and general management positi t th F i G itions at the Fresenius Group
  • Prior to joining Fresenius, Mr. Holstein spent several years in the consulting y, p industry, with positions in Frankfurt and London

Contents

R i 2010 Review

  • Pipeline
  • Th l echnology
  • AbD Serotec
  • Financials
  • Outlook 2011
  • Pipeline
  • Technology
  • AbD Serotec
  • Financials

Pipeline

The number of HuCAL antibodies in clinical development more than doubled in 2010

Growing Significance of the MorphoSys Pipeline

R f I di i f Cli i l C did P B d Range o ndicat ions o nicaCandidates Proves BroaUtility of MorphoSys´s Therapeutic Antibodies

HuCAL Drugs Target Large Markets

D
r
u
g		 M
k
t
a
r
e		 M
k
S
i
t
a
r
e
z
e
Q
B
H
8
8
0		 O
l
i
b
d
i
t
t
s
e
o
y
c
o
n
e
s
e
a
s
e		 \$
b
1
n
>
O
M
R
1
0
3		 R
h
i
d
h
i
i
(
R
A
)
t
t
t
e
m
a
o
a
r
r
s
u
(
S
)
M
l
i
l
l
i
M
t
u
p
e
s
c
e
r
o
s
s		 \$
b
5
n
>
\$
b
5
n
>
C
O
N
T
8
8
8		 P
C
t
t
r
o
s
a
e
a
n
c
e
r
I
d
i
h
i
l
f
i
b
i
(
I
P
F
)
t
o
p
a
c
p
m
o
n
a
r
r
o
s
s
u
y		 \$
b
5
n
>
\$
b
1
n
>
G
b
t
t
a
n
e
n
e
r
u
m
a		 A
l
h
h
i
i
'
's
d
d
i
i
(
A
D
)
z
e
m
e
r
s
e
a
s
e		 \$
b
5
n
>

Source: GBI Research Datamonitor MorphoSys estimates Research, Datamonitor,

M h S H B il O f h I d Morp hoSys Has uilt One of the ndustry ´s B d roadest Antibody Pipelines

MOR103, py Mor phoS y sNovartisCNTO888, Centocor Ortho Biotech (2 Programs) Gantenerumab, Roche BHQ880, Novartis MOR208, MorphoSys CNTO 1959, Centocor Ortho Biotech CNTO 3157 3157, C t O th Bi t h Centocor Ortho otecCentocor Ortho BiotechBAY79-4620, Bayer Schering Novartis (3 Programs) Boehringer Ingelheim PfizerOMP-59R5, OncoMed MOR202, MorphoSys 20 Partnered Programs 37 Programs (incl. 5 Proprietary Programs,

Co Development

Leading Technology Platforms HuCAL Slonomics g gy Source of therapeutic d di ti Generation of customized and diagnostic t i lib i antibodiesprotein libraries

Technology

New Partnerships Through New Technologies

Patent Protection on Platform Expanded Significantly

Patent lifetime on key platform technologies technologies

*Patent applications filed

AbD Serotec

Number of diagnostic HuCAL antibody projects at AbD Serotec

Diagnostic HuCAL Antibody Projects

D
i
s
e
a
s
e		 P
t
a
r
n
e
r		 A
i
b
d
t
n
o
y
G
i
t
e
n
e
r
a
o
n		 D
l
t
e
v
e
o
p
m
e
n		 R
l
A
l
t
e
g
u
a
o
r
y
p
p
r
o
v
a		 M
k
t
a
r
e
Au
im
t
o
m
u
ne		 P
ha
d
ia
R
he
i
d
Ar
hr
i
is
t
t
t
u
m
a
o		 Pr
i
ka
t
o
e
o
m
C
a
nc
e
r		 d.
n.
R
he
i
d
Ar
hr
i
is
t
t
t
u
m
a
o		 d.
n.
Au
im
D
is
t
o
m
ne
e
a
s
e
s
u		 d.
n.
M
l
He
l
hc
t
t
a
e
rn
a
a
a
re		 d.
n.
Im
S
io
m
u
ne
u
p
p
re
s
s
n		 d.
n.
C
d
ia
a
r
c		 A
b
D
S
t
e
ro
e
c
C
/
O
he
D
is
t
a
nc
e
r
r
e
a
s
e
s		 d.
n.
M
la
ia
a
r		 F
I
N
D
d.
n.		 d.
n.
d.
n.		 d.
n.

Financial Review 2010

Financial Review 2010

Increased R&D investment and still solid profits

FY2010: Operating Result

i
i
l
l
i
€
n
m
o
n		 2
0
1
0		 2
0
0
9		 C
h
a
n
g
e
R
e
v
e
n
u
e
s		 8
0
7		 8
1.
0		 %
7
C
f
G
d
S
l
d
t
o
s
o
o
o
s
o		 7
3		 6
7		 9
%
R
h
d
D
l
E
t
e
s
e
a
r
c
a
n
e
v
e
o
p
m
e
n
x
p
e
n
s
e
s		 4
6
9.		 3
9
0.		 2
0
%
S
l
G
l
&
A
d
i
i
i
E
t
t
a
e
s
e
n
e
r
a
m
n
s
r
a
e
p
e
n
s
e
s
v
x
,		 2
3
2		 2
3
9		 (
)
3
%
T
l
O
i
E
t
t
o
a
p
e
r
a
n
g
x
p
e
n
s
e
s		 4
7
7		 6
9
6		 1
1
%
i
O
h
O
I
t
t
e
r
p
e
r
a
n
g
n
c
o
m
e		 0
2		 0
1		 1
0
0
%
P
f
i
f
O
i
*
t
t
r
o
r
o
m
p
e
r
a
o
n
s		 9
8		 1
1
4		 (
1
4
%
)

* Differences dueto rounding

Results by Segment

i
i
l
l
i
€
n
m
o
n		 2
0
1
0		 2
0
0
9
P
t
a
r
n
e		 d
D
i
r
e
s
c
o
v
e
r
y
S
R
t
e
g
m
e
n
e
e
n
e
s
v
u		 6
6
3		 6
1
7
O
i
E
t
p
e
r
a
n
g
x
p
e
n
s
e
s		 2
3
6.		 2
2
1.
S
R
l
t
t
e
g
m
e
n
e
s
u		 4
2
7		 3
9
6
P
i
t
r
o
p
r
e		 D
l
t
a
r
y
e
v
e
o
p
m
e
n
S
R
R
t
t
e
g
m
e
n
e
v
e
n
u
e
s		 1
8.		 1
0.
O
i
E
t
p
e
r
a
n
g
x
p
e
n
s
e
s		 2
6
5		 1
9
3
O
O
h
i
I
t
t
e
r
p
e
r
a
n
g
n
c
o
m
e		 0
2		 0
S
R
l
t
t
e
g
m
e
n
e
s
u		 (
)
2
4
5		 (
)
1
8
3
A
b
D
S
t
e
r
o
e
c
S
R
t
e
g
m
e
n
e
v
e
n
u
e
s		 2
0
2		 1
9
3
O
i
E
t
p
e
r
a
n
g
x
p
e
n
s
e
s		 1
8
9		 1
8
4
O
O
h
i
I
t
t
e
r
p
e
r
a
n
g
n
c
o
m
e		 0
0
2		 0
1
S
R
l
*
t
t
e
g
m
e
n
e
s
u		 1
2		 1
0

* Differences due to rounding

Investment Into Proprietary R&D

Split of MorphoSys's investment in proprietary development in 2010

Condensed Balance Sheet

i
i
l
l
i
€
n
m
o
n		 2
0
1
0		 2
0
0
9
A
t
s
s
e
s
C
C
h
h
E
i
l
&
M
k
b
l
t
t
a
s
a
s
q
q
u
v
a
e
n
s
a
r
e
a
e
,
,
S
i
i
t
e
c
r
e
s
u		 1
1
0
0
8
8
4
4		 1
1
3
3
1
1
5
5
O
h
C
A
t
t
t
e
r
r
r
e
n
s
s
e
s
u		 2
4
1		 2
0
5
C
C
T
l
N
N
A
t
t
t
t
o
a
o
o
n
n-
u
u
r
r
r
r
e
e
n
n
s
s
e
s		 8
0
0.		 0
5
5.
T
l
A
*
t
t
o
a
s
s
e
s		 2
1
2
6		 2
0
6
1
i
i
i
i
L
b
l
t
a
e
s
C
T
l
L
i
b
i
l
i
i
t
t
t
o
a
r
r
e
n
a
e
s
u		 2
1.
4		 2
4
3
T
l
N
C
L
i
b
i
l
i
i
t
t
t
o
a
o
n-
r
r
e
n
a
e
s
u		 5
3		 7
9
T
l
S
S
h
h
h
h
l
l
d
d
'
E
i
t
t
o
a
a
a
r
r
e
e
o
o
e
e
r
r
s
s
q
u
y		 1
8
5
9.		 1
7
3
9.
T
l
L
i
b
i
l
i
i
t
t
o
a
a
e
s		 2
1
2
6		 2
0
6
1

* Differences dueto rounding

Shareholder Structure

Employees

2
0
1
0		 2
0
0
9
T
l
E
l
t
o
a
m
p
o
e
e
s
y		 4
6
4		 4
0
4
S
G
h
i
l
i
t
e
o
g
r
a
p
c
p
G
e
r
m
a
n
y		 3
7
0		 3
0
1
U
K		 7
8		 8
3
U
S
A		 1
6		 2
0
S
S
l
i
t
t
e
g
m
e
n
p
P
d
D
i
t
a
r
n
e
r
e
s
c
o
e
r
v
y		 1
8
3		 1
4
4
P
i
D
l
t
t
r
o
p
r
e
a
r
y
e
v
e
o
p
m
e
n		 1
0
0		 1
7
S
A
b
D
t
e
r
o
e
c		 1
4
2		 1
4
8
U
l
l
d
t
n
a
o
c
a
e		 3
9		 4
1

Share Price Performance

Results Q1 2011

I
€
i
l
l
i
n
m
o
n		 Q
1
2
0
1
1		 Q
1
2
0
1
0
R
e
v
e
n
u
e
s		 4
8
6		 2
0
6
C
O
G
S		 1.
8		 1.
7
R
&
D
E
x
p
e
n
s
e
s		 1
2
7		 9
3
S
G
&
A
E
p
e
n
s
e
s
x
,		 5
3		 4
9
T
l
O
i
E
t
t
o
a
p
e
r
a
n
g
x
p
e
n
s
e
s		 1
9
9		 1
5
9
O
O
h
i
E
t
t
e
r
p
e
r
a
n
g
x
p
e
n
s
e
s		 0
1		 0
0
1
i
f
i
O
P
t
t
p
e
r
a
n
g
r
o		 2
8
8		 4
7

Outlook 2011

Number of Proprietary Clinical Programs to Double in 2011

Partnered Pipeline Continues to Advance & Mature

Expected number of new program starts in 2011

Expected number of new clinical programs with partners

˃€100m

Estimated investment of partners in clinical trials with HuCAL antibodies

Technology Development will Lead to New Offering

antibodies

AbD S P i d E l i O i i Serotec oised to Exp oit Opportun ties in Diagnostics Market

HuCAL-based diagnostic kit close to market

Investment for Growth

Guidance: +20% Revenue Growth, Continued Investment

i
i
l
l
i
€
n
m
o
n		 2
0
1
1		 2
0
1
0
G
R
r
o
p
e
e
n
e
s
u
v
u		 1
0
1
1
0
5
-		 8
0
7
I
i
P
i
R
&
D
t
t
t
n
e
s
m
e
n
n
r
o
p
r
e
a
r
v
y		 4
0
4
5
-		 2
6
5
i
f
i
G
O
P
t
t
r
o
p
p
e
r
a
n
g
r
o
u		 1
0
1
3
-		 9
8
i
i
l
l
i
€
n
m
o
n		 2
0
1
1		 2
0
1
0
S
S
A
b
D
R
t
t
e
r
o
e
c
e
g
m
e
n
e
e
n
e
s
v
u		 2
2
2
3
-		 2
0
2.
S
f
i
i
A
b
D
P
M
t
t
e
r
o
e
c
r
o
a
r
g
n		 4
%
~		 6
%

A l G l M i 2011 AnnuaGeneraMeet ing Agenda

    1. P t ti f th fi d l fi i l t t t f D b 31 2010 th Presentation of the confirme d annual financial statements as of December 31, 2010, the management report together with the consolidated financial statements, the consolidated management report and the report of the Supervisory Board for the business year 2010 and the statement of the Board of Management to the items pursuant to § § 289 para. 4 315 ,para. 4 HGB
    1. Formal approval on behalf of the Board of Management
    1. Formal approval on behalf of the Supervisory Board
  • 4.Appointment of the auditors for the business year 2011 for year
    1. New Election to the Supervisory Board
    1. Resolution on the Approval of the Remuneration Scheme of Members of the Board of Management
    1. Resolution on the Authorization to purchase and use Treasur y Stock and on the Exclusion of Subscription Rights
    1. Creation of a new Conditional Capital 2011-I, authorization on behalf of the Board of Management t i ti d/ tibl b d l i f S b i ti Ri ht A d t f th to issue option and/or convertible bonds, exclusion of ubscription Rights; Amendment of the Articles
    1. Compensation of the Supervisory Board by Secondary Payments of the Company, Amendment of the Articles

MorphoSys thanks its Shareholders!

More from MorphoSys AG

AGM Information 2024
Aug 27
Delisting Announcement 2024
Aug 5
AGM Information 2024
Jul 19
AGM Information 2024
Jul 19
Declaration of Voting Results & Voting Rights Announcements 2024
Jul 18
Delisting Announcement 2024
Jul 12
Legal Proceedings Report 2024
Jul 12
Report Publication Announcement 2024
Jul 5
Major Shareholding Notification 2024
Jul 2
Declaration of Voting Results & Voting Rights Announcements 2024
Jun 21
View all filings →